top of page

Black Diamond Therapeutics' CEO on the company's 'MasterKey' approach to precision oncology

  • blonca9
  • Mar 4, 2024
  • 1 min read

Mark Velleca describes Black Diamond's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once, and updates us on lead programs targeting EGFR and BRAF.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page